[go: up one dir, main page]

WO2005072055A9 - Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation - Google Patents

Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation Download PDF

Info

Publication number
WO2005072055A9
WO2005072055A9 PCT/IB2005/000995 IB2005000995W WO2005072055A9 WO 2005072055 A9 WO2005072055 A9 WO 2005072055A9 IB 2005000995 W IB2005000995 W IB 2005000995W WO 2005072055 A9 WO2005072055 A9 WO 2005072055A9
Authority
WO
WIPO (PCT)
Prior art keywords
methods
natriuretic peptide
brain natriuretic
peptide variants
novel brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/000995
Other languages
English (en)
Other versions
WO2005072055A2 (fr
Inventor
Gad S. Cojocaru
Alexander Diber
Amit Novik
Sarah Pollock
Zurit Levine
Yossi Cohen
Michal Ayalon-Soffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen USA Inc
Original Assignee
Compugen USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen USA Inc filed Critical Compugen USA Inc
Priority to EP05718453A priority Critical patent/EP1730181A2/fr
Priority to CA002554599A priority patent/CA2554599A1/fr
Priority to AU2005207886A priority patent/AU2005207886A1/en
Priority to JP2006550367A priority patent/JP2007525213A/ja
Priority claimed from US11/043,590 external-priority patent/US7332569B2/en
Publication of WO2005072055A2 publication Critical patent/WO2005072055A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005072055A9 publication Critical patent/WO2005072055A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
PCT/IB2005/000995 2004-01-27 2005-01-27 Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation Ceased WO2005072055A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05718453A EP1730181A2 (fr) 2004-01-27 2005-01-27 Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation
CA002554599A CA2554599A1 (fr) 2004-01-27 2005-01-27 Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation
AU2005207886A AU2005207886A1 (en) 2004-01-27 2005-01-27 Novel brain natriuretic peptide variants and methods of use thereof
JP2006550367A JP2007525213A (ja) 2004-01-27 2005-01-27 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US53912704P 2004-01-27 2004-01-27
US60/539,127 2004-01-27
US58785104P 2004-07-15 2004-07-15
US60/587,851 2004-07-15
US60724604P 2004-09-07 2004-09-07
US60/607,246 2004-09-07
US62201604P 2004-10-27 2004-10-27
US62232004P 2004-10-27 2004-10-27
US60/622,320 2004-10-27
US60/622,016 2004-10-27
US62819004P 2004-11-17 2004-11-17
US60/628,190 2004-11-17
US11/043,590 US7332569B2 (en) 2004-01-27 2005-01-27 Brain natriuretic peptide spliced variant
US11/043,590 2005-01-27

Publications (2)

Publication Number Publication Date
WO2005072055A2 WO2005072055A2 (fr) 2005-08-11
WO2005072055A9 true WO2005072055A9 (fr) 2011-02-17

Family

ID=34831546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000995 Ceased WO2005072055A2 (fr) 2004-01-27 2005-01-27 Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation

Country Status (4)

Country Link
EP (1) EP1730181A2 (fr)
AU (1) AU2005207886A1 (fr)
CA (1) CA2554599A1 (fr)
WO (1) WO2005072055A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638443B1 (fr) 2003-06-20 2010-10-20 Mayo Foundation For Medical Education And Research Isoformes pour peptide natriuretique du cerveau
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
EP2001518B1 (fr) 2006-03-30 2013-07-10 Palatin Technologies, Inc. Constructions de peptides natriurétiques cycliques
TW200817431A (en) * 2006-08-08 2008-04-16 Mayo Foundation Diuretic and natriuretic polypeptides
BRPI0716228A2 (pt) 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
US9086408B2 (en) 2007-04-30 2015-07-21 Nexus Dx, Inc. Multianalyte assay
WO2009036448A2 (fr) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Agonistes des récepteurs peptidiques natriurétiques de type c
WO2010077634A1 (fr) 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
KR101226165B1 (ko) 2009-07-23 2013-01-24 가부시키가이샤 이기스 피부 외용제 조성물
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита
CA2823066A1 (fr) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions contenant des peptides natriuretiques et leurs methodes d'utilisation
EP2666475B1 (fr) 2011-01-21 2017-08-16 Igisu Co., Ltd. Agent thérapeutique pour l'alopécie
EP2744506B1 (fr) * 2011-08-18 2019-10-09 Upstream Medical Technologies Limited Produits thérapeutiques cardiovasculaires
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (fr) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Traitement de crise avec une phosphatase alcaline recombinee
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US12221495B2 (en) 2015-05-29 2025-02-11 Igisu Co., Ltd. Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (fr) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
WO2017074466A1 (fr) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
EP3426286A4 (fr) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (fr) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa le traitement de la trachéobronchomalacie
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
CA3057502A1 (fr) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2005072055A2 (fr) 2005-08-11
EP1730181A2 (fr) 2006-12-13
AU2005207886A1 (en) 2005-08-11
CA2554599A1 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2005072055A9 (fr) Nouveaux variants de peptides cerebraux natriuretiques et leurs procede d'utilisation
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL178593A (en) Specific antibodies of fcγriib and methods for their use
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL177242A0 (en) Anti-cd38 human antibodies and uses therefor
SI2511297T1 (sl) Proti -CD38 humana protitelesa in njihova uporaba
IL176958A0 (en) Compounds and methods of use
EP1660013A4 (fr) Biomateriaux et biocoacervats proteiniques, leurs procedes de fabrication et d'utilisation
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
EP1794589A4 (fr) Reseaux de proteines et leurs procedes d'utilisation
ZA200607582B (en) Anti-parasitic compounds and methods of their use
GB2401094B (en) Labels and methods of manufacture thereof
EP1812451A4 (fr) Composes et methodes d'utilisation de ces composes
ZA200601991B (en) Process for the preparation of renzapride and intermediates thereof
ZA200606319B (en) Anti-CD38 human antibodies and uses therefor
WO2005033343A8 (fr) Nouveaux variants d'epissage du gene dkkl1 humain
ZA200510465B (en) Use of a novel eimeria gene and corresponding protein
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003297218A1 (en) Npc1l1 (npc3) and methods of use thereof
IL177868A0 (en) Anti-inflammatory peptides and methods of use thereof
EP1697349A4 (fr) Analogues de doxepine et leurs methodes d'utilisation
EP1735334A4 (fr) Proteines set1 et utilisations associees
AU2003296232A1 (en) A human liver regeneration associated protein and the use of it
AU2004906706A0 (en) Peptides and methods of using same
AU2003260487A8 (en) Novel pancortin-pablo protein interactions and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2554599

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006550367

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005207886

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase in:

Ref document number: 2005207886

Country of ref document: AU

Date of ref document: 20050127

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005207886

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005718453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005718453

Country of ref document: EP